LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

2.98 -2.93

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.84

Max

3.07

Galvenie mērījumi
By Trading Economics
Ienākumi	183K -27M
Darbinieki	166
EBITDA	9.4M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+128.76% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 24. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	65M 161M
Iepriekšējā atvēršanas cena	5.91
Iepriekšējā slēgšanas cena	2.98

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.23 / 1.45 Atbalsts un pretestība

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. marts 19:18 UTC

Galvenie tirgus virzītāji

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

2026. g. 11. marts 23:54 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 11. marts 23:54 UTC

Tirgus saruna

Nikkei May Decline on Energy Costs Concerns -- Market Talk

2026. g. 11. marts 23:51 UTC

Tirgus saruna

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

2026. g. 11. marts 23:41 UTC

Tirgus saruna

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

2026. g. 11. marts 23:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

2026. g. 11. marts 23:17 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

2026. g. 11. marts 23:17 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

2026. g. 11. marts 22:29 UTC

Tirgus saruna

Australia Shares Set to Fall in Early Trade -- Market Talk

2026. g. 11. marts 21:47 UTC

Peļņas

Liontown Resources: Market Tailwinds Strengthening Outlook

2026. g. 11. marts 21:46 UTC

Peļņas

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

2026. g. 11. marts 21:45 UTC

Peļņas

Liontown Resources Says FY26 Guidance Unchanged

2026. g. 11. marts 21:45 UTC

Peļņas

Liontown Resources 1H Unit Operating Costs A$985/Ton

2026. g. 11. marts 21:44 UTC

Peļņas

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

2026. g. 11. marts 21:43 UTC

Peļņas

Liontown Resources 1H Revenue A$207.5 Million

2026. g. 11. marts 21:43 UTC

Peļņas

Liontown Resources 1H Net Loss A$184 Million

2026. g. 11. marts 21:12 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

2026. g. 11. marts 21:10 UTC

Peļņas

Vista Gold FY25 Loss $7.5M >VGZ

2026. g. 11. marts 21:10 UTC

Peļņas

Vista Gold FY25 Loss/Shr 6c >VGZ

2026. g. 11. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 11. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 11. marts 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Papa John's Draws Fresh Takeover Interest -- 2nd Update

2026. g. 11. marts 20:26 UTC

Peļņas

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

2026. g. 11. marts 20:19 UTC

Galvenie ziņu notikumi

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

2026. g. 11. marts 20:15 UTC

Peļņas

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

2026. g. 11. marts 20:12 UTC

Galvenie ziņu notikumi

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

2026. g. 11. marts 19:31 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

2026. g. 11. marts 19:01 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

2026. g. 11. marts 18:59 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

2026. g. 11. marts 18:43 UTC

Galvenie ziņu notikumi

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

128.76% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD 128.76%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.23 / 1.45Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.